A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS ...

The restructuring is only the latest round of layoffs to hit Arbutus after the company shed 40% of its staff and cut back on ...

Kezar reported new data Tuesday morning from a small Phase 2a study in autoimmune hepatitis, or AIH, a condition where the ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment of ...

Under the BioVersys and GSK collaboration agreement, GSK is evaluating the early bactericidal activity (EBA) of alpibectir-ethionamide (AlpE) in a pulmonary tuberculosis (TB) trial, in combination ...

Sobi announces a new research collaboration on the development of Gamifant in sepsis, which is to be presented at the ISICEM congress: Stockholm Thursday, March 20, 2025, 12:00 Hr ...

Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the publication of research in JAMA Neurology, which informs a possible therapeutic strategy to treat a rare ...

Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial -- ...

UCB, a global biopharmaceutical company, today announced it will present 8 scientific abstracts, including 3 late-breaker oral presentations, highlighting key data from its innovative ...

The Phase 1/2a clinical trial is a multicenter ... Led by Noriyuki Kasahara, MD, PhD, Principal Investigator, Brain Tumor Research Center (BTRC) at University of California, San Francisco ...